New NO product reduces diabetic pain

The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
In these producs a topical administration of nitric oxide has the potential becoming a new treatment concept for neuropathic pain in diabetics.

Nolabs develops innovative nitric oxide-containing medical devices based on the Nitrosense Technology. The core concept of Nitrosense Technology is combining an innovative substance and an innovative delivery system to create products for local delivery of nitric oxide. The company uses a system for local delivery of nitric oxide to different parts of the body. The major advantages of the Nitrosense Technology lie in the ability to deliver well-defined amounts of pure nitric oxide over shorter as well as longer time periods.

Significant unmet clinical need for diabetic patients and more than 200 million people suffer from diabetes globally. Peripheral diabetic neuropathy is one of the most common late complications, almost 40 per cent. It is frequently associated with pain, involving predominantly the lower limbs.

Kommentera en artikel
Meddela redaktionen
Se alla medlemsnyheter
Mest läst
Senaste nytt
Se senaste nytt
Utvalda artiklar
Utvalda nyheter från förstasidan
Fritt fram sprida desinformation om covid-19 på Twitter
Outsourcing som strategi för ökad trovärdighet
Roche lägger ner utveckling av Alzheimerbehandling
Viss effekt av Alzheimers-behandling bekräftas i studie – Bioarctic stiger på börsen
Astra Zeneca köper immunterapibolaget Neogene i miljardaffär
Svensk export av läkemedel ökar kraftigt
Andra Nordiska Medier
MedTech Magazine

Sänd till en kollega